id: underutilization_mineralocorticoid_antagonists_to_cardiovascular_disease_mortality
name: Underutilization of Mineralocorticoid Receptor Antagonists â†’ Cardiovascular
  Disease-Related Morbidity and Mortality
from_node:
  node_id: underutilization_mineralocorticoid_antagonists
  node_name: Underutilization of Mineralocorticoid Receptor Antagonists
to_node:
  node_id: cardiovascular_disease_mortality
  node_name: Cardiovascular Disease-Related Morbidity and Mortality
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Only 9.8% of Black adults with apparent treatment-resistant hypertension
  receive mineralocorticoid receptor antagonists despite American Heart Association
  recommendations'
- 'Step 2: 90.2% treatment gap results in suboptimal management of resistant hypertension
  in Black population'
- 'Step 3: Inadequate pharmacological control of blood pressure increases cardiovascular
  disease risk in high-risk population'
- 'Step 4: Elevated risk profile leads to increased cardiovascular morbidity and mortality
  outcomes'
evidence:
  quality_rating: C
  n_studies: 2
  primary_citation: Aisha T. Langford et al. 2020. "Underutilization of Treatment
    for Black Adults With Apparent Treatment-Resistant Hypertension." *HYPERTENSION*.
    https://doi.org/10.1161/HYPERTENSIONAHA.120.14836
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:05.452304'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: medication_cost_barriers
  direction: strengthens
  strength: moderate
  description: Economic barriers and insurance coverage limitations may reduce access
    to mineralocorticoid receptor antagonists
- name: provider_knowledge_guidelines
  direction: strengthens
  strength: moderate
  description: Provider awareness and adherence to 2018 AHA guidelines may influence
    prescribing rates
